Inotrem to initiate Phase IIa study of nangibotide for Covid-19
The trial will involve critically ill Covid-19 patients with features of systemic inflammation. Credit: INOTREM S.A.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more